Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular...

Area of Science:

• Cardiovascular Medicine
• Lipidology
• Preventive Cardiology

Background:

• Apolipoprotein B (apoB) is recognized as a more accurate marker for atherosclerotic cardiovascular disease (ASCVD) risk.
• Clinical adoption of apoB testing remains low, with routine care relying on low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (HDL-C), and triglycerides.
• This study investigates the sufficiency of standard lipid markers for cardiovascular risk assessment.

Purpose of the Study:

• To evaluate if LDL-C, non-HDL-C, and triglycerides are adequate surrogates for apoB in predicting ASCVD risk.
• To determine the variability of apoB across different levels of standard lipid markers.
• To assess the independent predictive value of apoB beyond standard lipid measurements.

Main Methods:

• Analysis of a large UK Biobank cohort (293,876 adults) with a median 11-year follow-up for new-onset ASCVD.
• Graphical examination of apoB distribution relative to LDL-C, non-HDL-C, and triglycerides.
• Construction of apoB residuals after accounting for standard lipids to assess independent predictive value for ASCVD events using proportional hazards regression.

Main Results:

• ApoB showed high correlation with LDL-C and non-HDL-C (r=.96), but lower with triglycerides (r=.42).
• Wide ranges of apoB values were observed at given levels of LDL-C, non-HDL-C, and triglycerides, indicating significant variability.
• Residual apoB independently predicted new-onset ASCVD events even after adjusting for LDL-C, non-HDL-C, and HDL-C, whereas standard lipid residuals did not remain significant when apoB was included.

Conclusions:

• Significant variability in apoB at standard lipid levels and its independent predictive power for ASCVD events demonstrate inadequacy of LDL-C, non-HDL-C, and triglycerides as sole risk assessment tools.
• ApoB provides crucial risk information not captured by conventional lipid profiles.
• Routine clinical care should consider apoB measurement for more accurate ASCVD risk stratification.